Literature DB >> 15901849

Mutations linked to autosomal dominant nocturnal frontal lobe epilepsy affect allosteric Ca2+ activation of the alpha 4 beta 2 nicotinic acetylcholine receptor.

Nivalda O Rodrigues-Pinguet1, Thierry J Pinguet, Antonio Figl, Henry A Lester, Bruce N Cohen.   

Abstract

Extracellular Ca(2+) robustly potentiates the acetylcholine response of alpha4beta2 nicotinic receptors. Rat orthologs of five mutations linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)-alpha4(S252F), alpha4(S256L), alpha4(+L264), beta2(V262L), and beta2(V262M)-reduced 2 mM Ca(2+) potentiation of the alpha4beta2 1 mM acetylcholine response by 55 to 74%. To determine whether altered allosteric Ca(2+) activation or enhanced Ca(2+) block caused this reduction, we coexpressed the rat ADNFLE mutations with an alpha4 N-terminal mutation, alpha4(E180Q), that abolished alpha4beta2 allosteric Ca(2+) activation. In each case, Ca(2+) inhibition of the double mutants was less than that expected from a Ca(2+) blocking mechanism. In fact, the effects of Ca(2+) on the ADNFLE mutations near the intracellular end of the M2 region-alpha4(S252F) and alpha4(S256L)-were consistent with a straightforward allosteric mechanism. In contrast, the effects of Ca(2+) on the ADNFLE mutations near the extracellular end of the M2 region-alpha4(+L264)beta2, beta2(V262L), and beta2(V262M)-were consistent with a mixed mechanism involving both altered allosteric activation and enhanced block. However, the effects of 2 mM Ca(2+) on the alpha4beta2, alpha4(+L264)beta2, and alpha4beta2(V262L) single-channel conductances, the effects of membrane potential on the beta2(V262L)-mediated reduction in Ca(2+) potentiation, and the effects of eliminating the negative charges in the extracellular ring on this reduction failed to provide any direct evidence of mutant-enhanced Ca(2+) block. Moreover, analyses of the alpha4beta2, alpha4(S256L), and alpha4(+L264) Ca(2+) concentration-potentiation relations suggested that the ADNFLE mutations reduce Ca(2+) potentiation of the alpha4beta2 acetylcholine response by altering allosteric activation rather than by enhancing block.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901849     DOI: 10.1124/mol.105.011155

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  The Ferrier Lecture 1998. The molecular biology of consciousness investigated with genetically modified mice.

Authors:  Jean-Pierre Changeux
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-12-29       Impact factor: 6.237

Review 2.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  Recent advances in gene manipulation and nicotinic acetylcholine receptor biology.

Authors:  Anne Tammimäki; William J Horton; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2011-06-16       Impact factor: 5.858

4.  Characterizing functional α6β2 nicotinic acetylcholine receptors in vitro: mutant β2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells.

Authors:  Cheng Xiao; Rahul Srinivasan; Ryan M Drenan; Elisha D W Mackey; J Michael McIntosh; Henry A Lester
Journal:  Biochem Pharmacol       Date:  2011-05-17       Impact factor: 5.858

5.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

Review 6.  Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.

Authors:  Henry A Lester; Cheng Xiao; Rahul Srinivasan; Cagdas D Son; Julie Miwa; Rigo Pantoja; Matthew R Banghart; Dennis A Dougherty; Alison M Goate; Jen C Wang
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

Review 7.  Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations.

Authors:  Ryan M Drenan; Henry A Lester
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

8.  In silico models for the human alpha4beta2 nicotinic acetylcholine receptor.

Authors:  Esmael J Haddadian; Mary Hongying Cheng; Rob D Coalson; Yan Xu; Pei Tang
Journal:  J Phys Chem B       Date:  2008-10-11       Impact factor: 2.991

9.  Distinctive effects of nicotinic receptor intracellular-loop mutations associated with nocturnal frontal lobe epilepsy.

Authors:  Maegan M Weltzin; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker
Journal:  Neuropharmacology       Date:  2015-11-10       Impact factor: 5.250

Review 10.  The road to discovery of neuronal nicotinic cholinergic receptor subtypes.

Authors:  Allan C Collins; Outi Salminen; Michael J Marks; Paul Whiteaker; Sharon R Grady
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.